ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) ...
After two days of gains, the market failed to extend its northward journey on January 3, as profit booking pulled the Nifty 50 down by 184 points on above-average volumes. However, the index managed ...